Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
Key facts
- Who runs it
- Hospices Civils de Lyon
- Where
- France8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 160 people, planned
- Started
- 21 Jul 2021
- Expected to end
- Jul 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- one additional blood sample during a planned blood test
- Record updated
- 19 July 2024
Who can take part
- Age
- 4 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Children 4 years of age or older or adults
- Having a clinical picture compatible with an FMF and a previous genetic analysis finding at least one mutation of the MEFV gene pathogenic or possibly pathogenic for the FMF group
- Newly diagnosed or in the process of follow-up (with no time limit or evolutionary criteria)
- During specific or non-specific treatment of the disease or without treatment
- For whom a blood test is planned as part of routine care
- Whose informed non-opposition has been collected (or parental non-opposition in the case of a minor patient)
Who cannot take part
- Known infections with HIV and / or HBV and / or HCV
- Person under legal protection or under the protection of justice or any other protective measures
- Person out of state to express their consent
- Person in emergency situation, vital or not
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Familial Mediterranean fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is caused by mutations in the MEFV gene, which encodes variants of the Pyrine inflammasome. Inflammasomes are protein complexes of the innate immunity that produce pro-inflammatory cytokines (interleukin-1β).
Read full original descriptionShow less
In vitro, our preliminary results demonstrated that the activation of the inflammatory pyrine (measured by the concentration of interleukin-1β) by kinase inhibitors is significantly increased in FMF patients compared to healthy subjects. Furthermore, a measurement of cell death gave significant results in differentiating the patients from the controls.
The performance of this functional has been tested, fast and simple diagnostic test on common mutations and wish to assess its characteristics for MEFV mutations.
The investigators hypothesize that this quick and simple functional test can serve as a diagnostic tool for FMF and can quantitatively discriminate against patients with different mutations (genotypes).
The 2 groups in the trial
- Children or adult with Familial Mediterranean fever
Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype. The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
Treatment: one additional blood sample during a planned blood test
- Healthy blood donor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 July 2024